Disruptive Growth & Healthcare Conference
New York City
The Disruptive Growth & Healthcare Conference will feature healthcare companies focusing on innovations to meet on unmet medical needs, as well as growth companies with disruptive technologies and business models. The audience is more than 400 institutional investors, accredited investors, family offices, analysts, registered investment advisors, wealth managers, RHK representatives and their clients – all of whom recognize the tremendous opportunities of disruptive ideas and their infinite potential at market introduction. For more information visit www.DisruptNYC.com
22nd Century (XXII)
22nd Century (NYSE: XXII) is a plant biotech company providing technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants and the level of cannabinoids in cannabis plants to be decreased or increased through genetic engineering and plant breeding. The company develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. For more information, visit the company's website at www.xxiicentury.com.
AcelRx Pharmaceuticals (ACRX)
AcelRx Pharmaceuticals (NASDAQ: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. An NDA for DSUVIA (sufentanil sublingual tablet, 30 mcg) was recently submitted to the FDA for review. The company's follow on product, ZALVISO® (sufentanil sublingual tablet system), designed for the management of moderate-to-severe acute pain in adult patients in the hospital setting, is currently enrolling patients in a phase 3 clinical trial, IAP312. For more information, visit the company's website at www.acelrx.com.
Auxilio (OTCQB: AUXOD) provides complete document workflow solutions and IT security services to healthcare organizations across the United States. The company has helped its clients save more than $80 million since 2004 by providing solutions which lower costs, improve operational efficiency and enhance security. Auxilio's iPLATFORM, an intelligent workflow automation suite delivers a customer driven, vendor neutral approach to secure patient health information, reduce waste and drive additional savings opportunities. Auxilio serves a national portfolio of nearly 220 hospital campuses and manages over 1.5 billion documents annually from over 90,000 devices supporting over 280,000 caregivers. For more information, visit the company's website at www.auxilioinc.com.
BioTime (NYSE: BTX) is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The foundation of BioTime's core therapeutic technology platform is pluripotent cells, which are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products. For more information, visit the company's website at www.biotimeinc.com.
Capstone Turbine (CPST)
Capstone Turbine (NASDAQ: CPST) develops, manufactures, markets and services microturbine technology solutions for use in stationary distributed power generation applications worldwide. The company offers microturbine units, subassemblies, components and various accessories for applications, including cogeneration comprising combined heat and power (CHP) and integrated CHP, as well as combined cooling, heat and power; and renewable energy, natural resources, and critical power supply. Its microturbines are also used as battery charging generators for hybrid electric vehicle applications. For more information, visit the company website at www.capstoneturbine.com.
Cemtrex (NASDAQ:CETX) is a diversified industrial and manufacturing company that provides a wide array of solutions to meet today's technology challenges. Cemtrex provides manufacturing services of advanced custom engineered electronics, industrial services, monitoring instruments for industrial processes and environmental compliance, and systems for controlling particulates, hazardous gases, emissions of Greenhouse gases, and other regulated pollutants used in emissions trading globally. For more information, visit the company's website at www.cemtrex.com.
Chanticleer Holdings (HOTR)
Chanticleer Holdings (NASDAQ: HOTR) is a leading company that owns, operates and franchises fast casual and full service dining concepts in the United States and internationally. Chanticleer owns and operates restaurants under the Hooters, American Burger Company, The Burger Joint, BT's Burger Joint, Little Big Burger, and Just Fresh names. For more information, visit the company's website at www.chanticleerholdings.com.
Check-Cap (NASDAQ: CHEK) is a clinical-stage medical diagnostics company developing the world's first ingestible capsule system for preparation-free, less-invasive colorectal cancer screening. The capsule utilizes innovative ultra-low dose X-ray and wireless communication technologies to scan the inside of the colon as it moves naturally, while the patient follows his or her normal daily routine. After passage, the system generates a 3D map of the inner surface of the colon which enables detection of polyps and cancer. Designed to increase the willingness of individuals to participate in recommended colorectal cancer screening, the Check-Cap system addresses many frequently-cited barriers, including laxative bowel preparation, invasiveness, and sedation. The Check-Cap system is currently not cleared for marketing in any jurisdiction. For more information, visit the company's website at www.check-cap.com.
CombiMatrix (NASDAQ: CBMX) provides best-in-class molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. The company specializes in pre-implantation genetic diagnostics and screening, prenatal diagnosis, miscarriage analysis and pediatric developmental disorders, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix's testing focuses on advanced technologies, including single nucleotide polymorphism ("SNP") chromosomal microarray analysis ("CMA"), next generation sequencing ("NGS"), fluorescent in situ hybridization ("FISH") and high resolution karyotyping. For more information, visit the company's website at www.combimatrix.com.
Cytori Therapeutics (CYTX)
Cytori Therapeutics (NASDAQ: CYTX) develops cellular therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy consisting of a heterogeneous population of specialized cells, including stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, urinary incontinence, and thermal burns combined with radiation injury. It also offers Celution System devices, proprietary enzymes, and sterile consumable sets to commercial customers, as well as for research customers developing new therapeutic applications for Cytori Cell Therapy. For more information, visit the company's website at www.cytori.com.
CytoSorbents (NASDAQ: CTSO) is a critical care focused immunotherapy company engaged in the research, development and commercialization of medical devices with its platform blood purification technology that incorporates a proprietary adsorbent polymer technology. Its principal product is the CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis. CytoSorbent is also developing the HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients. For more information, visit the company's website at www.cytosorbents.com.
Delcath Systems (DCTH)
Delcath Systems (NASDAQ: DCTH) operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver. The company is developing its proprietary product-Melphalan Hydrochloride for injection for use with the Delcath Hepatic Delivery System; and markets melphalan hydrochloride as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan in Europe. Its primary focus is on the execution of its clinical development program in ocular melanoma liver metastases, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and certain other cancers that are metastatic to the liver. For more information, visit the company's website at www.delcath.com.
Immune Pharmaceuticals (IMNP)
Immune Pharmaceuticals (NASDAQ: IMNP) is focused on developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company's lead product candidate, bertilimumab, is in phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan autoimmune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn's disease, severe asthma and Non-Alcoholic Steato-Hepatitis (NASH), an inflammatory liver disease. Immune's portfolio in immuno-dermatology includes a treatment for psoriasis and atopic dermatitis. Its oncology pipeline includes Ceplene® for maintenance remission in Acute Myeloid Leukemia (AML) in combination with IL-2; and Azixa® and crolibulin, phase II clinical stage vascular disrupting agents, and novel technology platforms. The company's Maxim Pharmaceuticals Inc. subsidiary is developing AmiKet™ and AmiKet™ Nano™ for the treatment of neuropathic pain. For more information, visit the company's website at: www.immunepharma.com.
IntelliPharmaCeutics International (IPCI)
IntelliPharmaCeutics International (NASDAQ: IPCI) is a pharmaceutical company that engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs. The company develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders. For more information, visit the company's website at www.intellipharmaceutics.com.
Inventergy Global (INVT)
Inventergy Global (NASDAQ: INVT) operates as an intellectual property (IP) investment and licensing company. It offers corporate licensing model for IP value creation that provides short term returns and long-term licensing revenue. Inventergy acquires portfolios in the telecommunications' industry, primarily in core network infrastructure and mobile broadband communications segments. It is dedicated to identifying, acquiring and licensing patented technologies of market-significant technology leaders and small companies. For more information, visit the company's website at www.inventergy.com.
IsoRay (NYSE: ISR) develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. For more information, visit the company's website at www.isoray.com.
ITUS (NASDAQ: ITUS) funds, develops, acquires and licenses emerging technologies in the areas of biotechnology. The company, through its subsidiary, Anixa Diagnostics Corporation, is developing a platform called Cchek, a series of non-invasive, blood tests for the early detection of solid tumor based cancers. It has a collaborative research agreement with The Wistar Institute for the development and validation of Cchek. The company was formerly known as CopyTele, Inc. and changed its name to ITUS Corporation in September 2014. For more information, visit the company's website at www.ituscorp.com.
Lantronix (NASDAQ: LTRX) is a specialized networking company providing smart Internet of Things (IoT) and machine-to-machine (M2M) solutions. The company's innovative products deliver secure connectivity, device management, and mobility for today's increasingly connected world. By networking and managing devices and machines that have never before been connected, Lantronix's connectivity solutions are deployed inside millions of machines serving a wide range of industries, including data center, medical, security, industrial, transportation, retail, financial, environmental and government. For more information, visit the company's website at www.lantronix.com.
Lightbridge (NASDAQ: LTBR) is a nuclear fuel technology company that operates in two segments: technology and consulting. The company offers all-metal fuel for operating and new build reactors; all-uranium seed and blanket fuel for existing plants and new build reactors; and thorium-based seed and blanket fuel for existing and new build reactors. The company's services include integrated strategic advice across a range of areas, including regulatory development, nuclear reactor site selection, procurement and deployment, reactor and fuel technology, international relations, program management, regulatory affairs, and infrastructure development. For more information, visit the company website at www.ltbridge.com.
MagneGas (NASDAQ: MNGA) is an alternative energy company that creates and produces hydrogen-based alternative fuel through the gasification of carbon-rich liquids in the United States and internationally. The company produces gas bottled in cylinders and distributes to the metalworking market as an alternative to acetylene. It offers MagneGas, a fuel that primarily comprises hydrogen; and Plasma Arc Flow refineries that produce gas. The company also sells and licenses the plasma arc technology for the processing of liquid waste. For more information, visit the company's website at www.magnegas.com.
MTBC (NASDAQ: MTBC) is a health care information technology company that provides a fully integrated suite of proprietary web-based and mobile health solutions, together with related business services, to healthcare providers throughout the United States. The company's integrated SaaS platform helps its customers increase revenues, streamline workflows, and make better business and clinical decisions, while reducing administrative burdens and operating costs. For more information, visit the company's website at www.mtbc.com.
NABUFIT Global (NBFT)
NABUFIT Global (OTCQB: NBFT) is an online fitness platform for health and well-being through physical exercises, nutrition and lifestyle. The platform offers an interactive, customized experience founded on the workouts and participation of Sports Stars, including Neymar Jr., Mo Farah, Peter Schmeichel, Michael Maze, and many more to come. The development, headquartered in Denmark, is developing an online fitness platform and a mobile application that connects to existing and future monitoring devices such as wearables. For more information, visit the company's website at: www.nabufit.com.
Northwest Biotherapeutics (NWBO)
Northwest Biotherapeutics (OTCQB: NWBO) is focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The company's lead program is a 331-patient phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." Northwest is also pursuing a phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers. It has completed the 40-patient phase I portion of the trial, and is preparing for the phase II portion. The company previously conducted a phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania. For more information visit the company's website at: www.nwbio.com.
NuLife Sciences (NULF)
NuLife Sciences (OTCQB: NULF) is a biomedical company focused on advancing human organ transplant technology and medical research. NuLife has a patent protected unique proprietary method ("NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed discovery phase for its technique, and is now entering a Preclinical phase involving animal experiments on its pathway to commercialization.
OncoCyte (NYSE: OCX) focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancers. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder and breast cancers. For more information, visit the company's website at www.oncocyte.com.
Oncosec Medical (ONCS)
Oncosec Medical (NASDAQ: ONCS) is a biotechnology company that designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the company's therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. For more information, visit the company's website at www.oncosec.com.
Oramed Pharmaceuticals (ORMP)
Oramed Pharmaceuticals (NASDAQ: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The company completed multiple phase II clinical trials of ORMD-0801 under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901). For more information, visit the company's website at www.oramed.com.
Pluristem Therapeutics (PSTI)
Pluristem Therapeutics (NASDAQ: PSTI) operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trials and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions. It develops placenta expanded (PLX) products, including PLX-PAD cells that are in phase-II clinical trial for use in the treatment of peripheral and cardiovascular diseases, as well as for the treatment of orthopedic diseases. For more information, visit the company's website at www.pluristem.com.
Safeguard Scientifics (SFE)
Safeguard Scientifics (NYSE: SFE) provides capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media. The company targets companies that are capitalizing on the next wave of enabling technologies with a particular focus on the Internet of Everything, enhanced security and predictive analytics. Safeguard typically deploys between $5 million and $25 million over the course of its partnership with a company, initially investing in a Series A or B Round and opportunistically in a Seed Round. Safeguard has a distinguished track record of fostering innovation and building market leaders that spans more than six decades. For more information, visit the company's website at www.safeguard.com.
Soupman (OTC: SOUP) is a manufacturer and multi-channel marketer of premium soups that are offered under the "Original Soupman" brand. Together with its subsidiaries, Soupman manufactures and sells its products to grocery chains, school systems, and franchisees. Its license from Al Yeganeh, the legendary "soupman," provides the company with access to Yeganeh's recipes, name, likeness and other intellectual properties. It also franchises Original Soupman restaurants and mobile units, as well as other high-traffic locations such as casinos, airports, theme parks and other tourist locations. Soupman has nine franchise locations, including co-branded locations. For more information, visit the company's website at www.originalsoupman.com.